Drug
Deleobuvir clinical trials
Also written BI 207127.
Includes 7 studies of Deleobuvir sodium.
- studies test it
- 19
- open now
- 0
- in phase 3
- 2
- first study started
- 2007
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
19 studies that test it; most in 2013 (7)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 6 |
| 2013 | 7 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 13
- Phase 2
- 4
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 0
Boehringer Ingelheim (18) · Presidio Pharmaceuticals, Inc. (1)
Often tested with
Tested in the same studies.
Faldaprevir (9) · Ribavirin (5) · Midazolam (2) · Tolbutamide (2) · Faldaprevir sodium (2) · Tenofovir (1) · Caffeine (1) · Omeprazole (1)
Studies
Open first, then newest update. How each study uses deleobuvir is read from its arms, and is right about nine times in ten.
Testing it · 19
- Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected PatientsCompletedPhase 1Boehringer IngelheimNCT01525628Written as BI 207127
- Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected PatientsCompletedPhase 1Boehringer IngelheimNCT02176525Written as BI 207127 NA
- Effect of Food and Increased Gastric pH Value on Bioavailability of a Single Dose of BI 207127 in Healthy Caucasian and Japanese SubjectsTerminatedPhase 1Boehringer IngelheimNCT01983566Written as BI 207127 high fat
- Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian VolunteersCompletedPhase 1Boehringer IngelheimNCT01347086Written as BI 207127 NA (medium dose)
- Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.CompletedPhase 1Boehringer IngelheimNCT01965431Written as BI 207127
- This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis CCompletedPhase 2Boehringer IngelheimNCT01528735Written as BI 207127 NA
- Bioavailability of 3 Different Formulations of BI 207127 in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT01535638Written as BI 207127
- Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired PatientsTerminatedPhase 1Boehringer IngelheimNCT01957657Written as BI 207127
- Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and LevonorgestrelTerminatedPhase 1Boehringer IngelheimNCT01941615Written as BI 207127
- Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female SubjectsCompletedPhase 1Boehringer IngelheimNCT01737996Written as BI 207127 + faldaprevir
- Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT01605461Written as BI 207127 NA
- Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2CompletedPhase 3Boehringer IngelheimNCT01728324Written as BI 207127: 24-week treatment
- Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 InfectionCompletedPhase 2Boehringer IngelheimNCT01132313Written as BI 207127
- Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis CCompletedPhase 2Presidio Pharmaceuticals, Inc.NCT01859962Written as BI 207127 Dose 1
- BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3CompletedPhase 2Boehringer IngelheimNCT01830127Written as BI 207127 high dose
- Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy VolunteersCompletedPhase 1Boehringer IngelheimNCT02182414Written as BI 207127 NA (TF-I)
- Single Rising Oral Doses of BI 207127 NA as Powder in the Bottle in Healthy Male SubjectsCompletedPhase 1Boehringer IngelheimNCT02182388Written as BI 207127 NA powder for solution
- Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male VolunteersTerminatedPhase 1Boehringer IngelheimNCT02182401Written as BI 207127 NA
- Open Label Trial to Compare BI 207127 to Telaprevir in HCV PatientsWithdrawnPhase 3Boehringer IngelheimNCT01858961Written as BI 207127
Given in every arm · 1 — deleobuvir is usual care beside what is tested
Codes
What other systems call deleobuvir · ClinicalTrials.gg INT000095
- MeSH (NLM) C000592437deleobuvirOne source NLM
- UNII (FDA) 58BU988K90DELEOBUVIRConfirmed FDA, NLM, Wikidata
- Wikidata Q15708312deleobuvirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166826DeleobuvirOne source FDA
- DrugBank DB14850One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000592437 | deleobuvir | One source NLM |
| UNII (FDA) | 58BU988K90 | DELEOBUVIR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q15708312 | deleobuvir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166826 | Deleobuvir | One source FDA |
| DrugBank | DB14850 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.